Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by FORSYTH, D. R.
Right arrow Articles by WILCOCK, G. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FORSYTH, D. R.
Right arrow Articles by WILCOCK, G. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1989 Oxford University Press

research-article

Clinical Experience with and Side-effects of Tacrine Hydrochloride in Alzheimer's Disease: A Pilot Study

D. R. FORSYTH, D. J. SURMON, R. A. MORGAN and G. K. WILCOCK

Department of Care of the Elderly, Frenchay Hospital Bristol BS16 1LE

Address correspondence to Dr D. R. Forsyth, General/Geriatric Medicine, Royal Devon and Exeter Hospital (Wonford), Barrack Road, Exeter EX2 5DW

Pharmacological manipulation of central cholinergic neurotransmisson may prove beneficial in the treatment of Alzheimer's disease (AD) Tacrine hydrochloride is a central anticholinesterase which has been said to improve intellectual function in patients with AD. We report here our clinical experience with this drug in eight patients with AD, diagnosed according to DSM III and NINCDS-ADRDA criteria. Cholinergic side-effects occurred in five patients, three of whom tolerated a reduced dose. Liver function tests rose within the normal range in all patients and became abnormal in one.

Revision received February 1, 1989.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
M. Galisteo, M. Rissel, O. Sergent, M. Chevanne, J. Cillard, A. Guillouzo, and D. Lagadic-Gossmann
Hepatotoxicity of Tacrine: Occurrence of Membrane Fluidity Alterations without Involvement of Lipid Peroxidation
J. Pharmacol. Exp. Ther., July 1, 2000; 294(1): 160 - 167.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. F. Stachlewitz, G. E. Arteel, J. A. Raleigh, H. D. Connor, R. P. Mason, and R. G. Thurman
Development and Characterization of a New Model of Tacrine-Induced Hepatotoxicity: Role of the Sympathetic Nervous System and Hypoxia-Reoxygenation
J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1591 - 1599.
[Abstract] [Full Text]

Home page
 BMJHome page
N Maltby, G A Broe, H Creasey, A F Jorm, H Christensen, and W S Brooks
Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial
BMJ, April 2, 1994; 308(6933): 879 - 883.
[Abstract] [Full Text]

Home page
 Clin RehabilHome page
B. E McGuire
Review article : Psychopharmacological treatments for memory impairment
Clinical Rehabilitation, August 1, 1990; 4(3): 235 - 244.
[PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.